Great short and sweet review article on HDL sub-species, HDL lipoprotein metabolism and HDL dysfunction in diabetes. Here is the direct link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489613/
Resverlogix has already documented in previous clinical trials effects of apabetalone on apo-AI, HDL particle number, changes in HDL-cholesterol, changes in HDL size distribution and changes in the lipid composition of HDL. These previous trials were much smaller than BETonMACE and had very few diabetic patients relative to BETonMACE. Since the BETonMACE trial is all low-HDL, diabetic patients, I agree that there will likely be some insights into HDL biology and functionality in diabetics derived from BETonMACE.
As for the other article you cited on rosuvastatin, they did not compare rosuvastatin (Crestor) to any other statins in that study. Therefore, it is difficult to conclude any rosuvastatin-specific effects from this single study.
BearDownAZ